Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Biohacking has moved from niche experiments to a global movement reshaping how we think about human potential. With ...
A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.
The X contains more genes related to brain function than does any other chromosome. “The X chromosome may be a treasure trove ...
Key risks with CRISPR have migrated over time from concern about achieving end points in its trials, to whether the FDA would approve a CRISPR-based treatment, to know how successful that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback